[Infostock Daily= Reporter An Hoe Hyun] NH Investment & Securities predicted Classys's high growth of performance on the 15th due to COVID-19 calm down following the supply of vaccines in 2021. Investment opinion 'Buy' and target stock price of 21,000 won remained.
Classys operates medical devices, beauty devices, personal beauty devices and cosmetics businesses for beauty purposes.
This year, Classys's sales are expected to increase 27.7% year-on-year to 97.4 billion won and operating profit is expected to increase 35.3% to 58 billion won. It is believed that the recovery of exports will offset sluggish domestic demand.
Domestic sales and exports were estimated at 8.5 billion won and 12.2 billion won, respectively, in the fourth quarter of last year. Domestic demand fell 25.1% year-on-year and exports rose 10.4%.
"Although we expected a peak season effect at the end of the year, domestic operations were restricted in the aftermath of the 2.5 level of social distancing," the company explained, adding, "We were also concerned about exports due to the resurgence of COVID-19, but overseas operations and orders are on the rise in the absence of physical restrictions such as lock-down or shutdown."
Reporter An Hoe Hyun ahh@infostock.co.kr
